| SYK Stock | | | EUR 344.30 0.10 0.03% |
President
Mr. Timothy J. Scannell is President, Chief Operating Officer of the Company effective August 1, 2018. He began his career with Stryker in 1990 with our Endoscopy division, where he served in various sales and marketing leadership roles. Mr. Scannell progressed to the position of Executive Vice President, overseeing sales, marketing and operations. In 2001, he was appointed Vice President and General Manager of our Biotech division. In 2003, he was named Vice President and General Manager of our Spine division and was later promoted to President of Spine. In 2009, he was appointed to the position of Group President and initially was responsible for the Spine and Endoscopy divisions. Over time, the role expanded to include MedSurg and Neurotechnology, with each of the groups divisional leaders reporting to him. He serves on the Board of Directors for Insulet Corporationrationration, whose OmniPodInsulin Management System helps to improve the lives of people with diabetes. since 2018.
| Age | 58 |
| Tenure | 7 years |
| Phone | 269 385 2600 |
| Web | https://www.stryker.com |
Stryker Management Efficiency
The company has return on total asset
(ROA) of
0.0618 % which means that it generated a profit of $0.0618 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.1498 %, meaning that it generated $0.1498 on every $100 dollars invested by stockholders. Stryker's management efficiency ratios could be used to measure how well Stryker manages its routine affairs as well as how well it operates its assets and liabilities.
Stryker has accumulated 11.86
B in total debt with debt to equity ratio
(D/E) of 74.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Stryker has a current ratio of 2.03, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Stryker until it has trouble settling it off, either with new capital or with free cash flow. So, Stryker's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Stryker sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Stryker to invest in growth at high rates of return. When we think about Stryker's use of debt, we should always consider it together with cash and equity.
Stryker Corporation operates as a medical technology company. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan. STRYKER CORP operates under Medical Devices classification in Germany and is traded on Frankfurt Stock Exchange. It employs 36000 people. Stryker (SYK) is traded on Frankfurt Exchange in Germany and employs 51,000 people.
Management Performance
Stryker Leadership Team
Elected by the shareholders, the Stryker's board of directors comprises two types of representatives: Stryker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stryker. The board's role is to monitor Stryker's management team and ensure that shareholders' interests are well served. Stryker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stryker's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Cohen, CTO Replacement | |
| Alan Douville, Chief VP | |
| Kevin Lobo, President CEO, Director | |
| Glenn Boehnlein, CFO, Vice President | |
| Jason Beach, VP Relations | |
| Spencer Stiles, Group Spine | |
| Viju Menon, Group President - Global Quality and Business Operations | |
| Andrew Pierce, Group Neurotechnology | |
| William Berry, Principal Accounting Officer, Vice President Corporate Controller | |
| Timothy Scannell, Group President - MedSurg and Neurotechnology | |
Stryker Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stryker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Stryker Stock
When determining whether Stryker is a good investment, qualitative aspects like company
management, corporate governance, and ethical practices play a significant role. A
comparison with peer companies also provides context and helps to understand if Stryker Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stryker Stock.
Highlighted below are key reports to facilitate an investment decision about Stryker Stock: Check out
World Market Map to better understand how to build diversified portfolios, which includes a position in Stryker. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
For more detail on how to invest in Stryker Stock please use our
How to Invest in Stryker guide.
You can also try the
Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Please note, there is a significant difference between Stryker's value and its price as these two are different measures arrived at by different means. Investors typically determine if Stryker is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stryker's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.